Rileptid

PACKING

Oblong, slightly biconvex, light green, odourless, scored tablets embossed with stylistic E 752
inscription on one side, and a scoring line on the other side. Fracture surface is white.

POINT

Rileptid is indicated for the treatment of schizophrenia, moderate to severe manic episodes associated with bipolar disorders.
Rileptid is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others

MANUAL

Appointed 1 or 2 times / day. The initial dose - 2 mg / day. On the second day, the dose should be increased to 4 mg / day. 

CONTRAINDICATIONS

Hypersensitivity to the active substance or to any of the excipients.

Reducing productive symptoms of schizophrenia (delirium, hallucinations), automatism, at least causes the suppression of motor activity and to a lesser extent induces catalepsy, than classical neuroleptics. Balanced central serotonin antagonism and dopamine can reduce susceptibility to extrapyramidal side effects.